Aptar appoints Julie Xing to its board of directors

CRYSTAL LAKE - AptarGroup Inc. said Julie Xing has joined its board of directors.

Since 2022, Xing has served as executive chair of the board of Mundipharma China. Mundipharma is a global pharmaceutical leader. Prior to that, she held the position of global senior vice president, and president of Greater China, for Envista Holdings Corp.

With more than 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Xing's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and health care environments.

Xing's has also held numerous leadership roles at Eli Lilly and Co., including senior director, global new product planning and payer marketing, pricing, reimbursement and access of Lilly Diabetics; and vice president, corporate and government affairs and market access and vice president of Lilly China Oncology, while based in Shanghai.

Aptar is a leader in the design and manufacturing of a broad range of drug delivery products, consumer product packaging and active material science solutions and services.